Maria Vieito - Publications

Reply to: Prior BRAF Inhibitor Exposure Is Not Enough to Define Resistance in the Phase I Mosperafenib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 27, 2026

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Journal: Nature medicine

Published: June 29, 2026

Regulatory delay and lost opportunity in IDH-mutant low-grade glioma.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 26, 2026

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Journal: Nature medicine

Published: April 20, 2026

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 27, 2026

Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

Journal: Cancer research communications

Published: March 10, 2026

Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and Pitfalls.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 26, 2026

Targeting regulatory T cells for cancer immunotherapy: promises and pitfalls.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 26, 2026

Evolving landscape of targeted therapies in early phase clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 04, 2026

Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response.

Journal: Journal for immunotherapy of cancer

Published: November 30, 2025

Inequities in enrollment across clinical trial phases and the need for a Spanish perspective.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 24, 2025

Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort.

Journal: Cancer medicine

Published: September 08, 2025